Glucose-1-phosphate thymidylyltransferase (RmlA) and related dTDP-L-rhamnose biosynthesis enzymes (RmlA-D)

RmlA and its associated enzymes (RmlB, RmlC, and RmlD) constitute the biosynthetic pathway for dTDP-L-rhamnose, an essential precursor for the synthesis of various bacterial cell wall components, including the O-antigen of lipopolysaccharides and the rhamnogalactan-I of the mycobacterial cell wall (UniProt: P0A7H2; PMID: 22403114). This pathway is critical for the structural integrity and virulence of many Gram-negative and Gram-positive pathogens, such as Mycobacterium tuberculosis, Streptococcus pneumoniae, and Pseudomonas aeruginosa (PMID: 11514513). Because the dTDP-L-rhamnose biosynthesis pathway is entirely absent in humans, these enzymes represent highly attractive targets for the development of narrow-spectrum or broad-spectrum antibacterial agents with minimal off-target effects on the host (PMID: 17550215). Inhibition of any enzyme in this four-step sequence—starting with the activation of glucose-1-phosphate by RmlA—disrupts the production of L-rhamnose-containing glycoconjugates, leading to impaired bacterial growth or increased susceptibility to host immune defenses. Current drug discovery efforts focus on identifying small-molecule inhibitors, such as substrate analogs and high-throughput screening hits, to combat multi-drug resistant bacterial infections (PMID: 28604044). The pathway's conservation across diverse bacterial species makes it a promising candidate for novel antibiotic development in an era of increasing antimicrobial resistance.

Other names

dTDP-L-rhamnose biosynthetic pathwayRfb pathwayRml pathwayRfbARfbBRfbCRfbDGlucose-1-phosphate thymidylyltransferasedTDP-D-glucose 4,6-dehydratasedTDP-4-dehydrorhamnose 3,5-epimerasedTDP-4-dehydrorhamnose reductase

Inhibition of the enzymatic conversion of glucose-1-phosphate to dTDP-L-rhamnose, thereby preventing the assembly of essential bacterial cell wall components and virulence factors.